Cost-effectiveness and lung cancer clinical trials.

  title={Cost-effectiveness and lung cancer clinical trials.},
  author={Wei Du and Jaxk H. Reeves and Shirish M. Gadgeel and Judith Abrams and William P. Peters},
  volume={98 7},
BACKGROUND Lung cancer is the leading cause of cancer death in the U.S., with an estimated annual economic burden of $5 billion. Clinical trials offer innovative therapeutic options with potentially better outcomes, but their effects on health care costs are disputed. METHODS The authors analyzed the 1-year facility-based treatment cost and survival of 336 newly diagnosed nonsmall cell lung cancer patients who were deemed eligible for clinical trials between 1994 and 1998 at the Karmanos… CONTINUE READING